Related references
Note: Only part of the references are listed.TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
Florent Dufour et al.
ONCOTARGET (2017)
Mining Naive Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility
Haiyong Peng et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1
Lu Guo et al.
JOURNAL OF CANCER (2017)
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Agathe Dubuisson et al.
ANTIBODIES (2017)
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study
Yun Leng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
Florent Dufour et al.
CELL DEATH AND DIFFERENTIATION (2017)
Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway
Zhichao Hao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo
Xiuhong Piao et al.
ONCOIMMUNOLOGY (2016)
Therapeutic Antibodies by Phage Display
Hyunbo Shim
CURRENT PHARMACEUTICAL DESIGN (2016)
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Yun Leng et al.
CHINESE JOURNAL OF CANCER (2016)
Principles of antibody-mediated TNF receptor activation
H. Wajant
CELL DEATH AND DIFFERENTIATION (2015)
Nanovectorization of TRAIL with Single Wall Carbon Nanotubes Enhances Tumor Cell Killing
Al Batoul Zakaria et al.
NANO LETTERS (2015)
Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion
A. Morle et al.
CELL DEATH & DISEASE (2015)
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
M. H. Tuthill et al.
ONCOGENE (2015)
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
Jonathan D. Graves et al.
CANCER CELL (2014)
An improved and robust DNA immunization method to develop antibodies against extra-cellular loops of multi-transmembrane proteins
Meredith Hazen et al.
MABS (2014)
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
Heather A. Huet et al.
MABS (2014)
Death receptors as targets in cancer
O. Micheau et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization
Chunhua Zhang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA
Marie P. Piechocki et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
A. Morizot et al.
CELL DEATH AND DIFFERENTIATION (2011)
Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
Zhigang Kang et al.
CLINICAL CANCER RESEARCH (2011)
TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT
Najoua Lalaoui et al.
PLOS ONE (2011)
Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types
Paula J. Kaplan-Lefko et al.
CANCER BIOLOGY & THERAPY (2010)
Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
Valeria Pavet et al.
CANCER RESEARCH (2010)
Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations
Prashant Bavi et al.
MOLECULAR CANCER (2010)
Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo
Motoo Nagane et al.
NEURO-ONCOLOGY (2010)
Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
Stephan Macher-Goeppinger et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer
Tom M. Ganten et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes
Eun-Sil Sung et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Troy A. Luster et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
Avi Ashkenazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
p53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells
F. Toscano et al.
ONCOGENE (2008)
Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L
D. Berg et al.
CELL DEATH AND DIFFERENTIATION (2007)
DNA versus protein immunisation for production of monoclonal antibodies against Choristoneura fumiferana ecdysone receptor (CfEcR)
DH Yang et al.
VACCINE (2006)
The REFOLD database: a tool for the optimization of protein expression and refolding
Michelle K. M. Chow et al.
NUCLEIC ACIDS RESEARCH (2006)
Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor related apoptosis-inducing ligand receptor 2
K Motoki et al.
CLINICAL CANCER RESEARCH (2005)
Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia
YJ Min et al.
LEUKEMIA RESEARCH (2004)
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy
K Takeda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
TRAIL receptor-2 signals apoptosis through FADD and caspase-8
JL Bodmer et al.
NATURE CELL BIOLOGY (2000)
Share Paper
